Table 2.
Crude Prevalence of and Vaccine Effectiveness (VE) Against Human Papillomavirus (HPV) Infection
| Variable | Overall, No. (%) (n = 1814) |
Vaccinated, No. (%) (n = 1355) |
Unvaccinated, No. (%) (n = 459) |
Univariate Analysis | Multivariate Analysisc | ||||
|---|---|---|---|---|---|---|---|---|---|
| PR (95% CI) | VE, % (95% CI) | P b | aOR (95% CI) | aVE, % (95% CI) | P | ||||
| High-risk HPVa | 226 (12.5) | 156 (11.5) | 70 (15.3) | 0.76 (.58–.98) | 24.5 (2.0–41.9) | .04d | 0.72 (.51–1.02) | 27.9 (−2.0–49.0) | .06 |
| HPV16/18 | 13 (0.7) | 3 (0.2) | 10 (2.2) | 0.10 (.03–.37) | 89.8 (63.9–97.2) | <.01d | 0.08 (.02–.33) | 91.9 (66.8–98.0) | <.01d |
| HPV16 | 11 (0.6) | 3 (0.2) | 8 (1.7) | 0.13 (.03–.48) | 87.3 (52.3–96.6) | <.01d | 0.11 (.03–.49) | 88.8 (51.0–97.5) | <.01d |
| HPV18 | 2 (0.1) | 0 (0.0) | 2 (0.4) | 0.00 … | 100.0 … | .06 | 0.00 … | 100.0 … | 1.00 |
| HPV31 | 8 (0.4) | 3 (0.2) | 5 (1.1) | 0.20 (.05–.85) | 79.7 (15.3–95.1) | .03d | 0.27 (.05–1.48) | 73.4 (−48.0–95.2) | .13 |
| HPV33 | 9 (0.5) | 7 (0.5) | 2 (0.4) | 1.19 (.25–5.69) | −18.6 (−468.7–75.3) | 1.00 | 1.30 (.22–7.86) | −30.0 (−686.0–78.4) | .77 |
| HPV35 | 5 (0.3) | 5 (0.4) | 0 (0.0) | ∞ … | −∞ … | .34 | >100 … | Less than −100.0 … | .99 |
| HPV39 | 22 (1.2) | 17 (1.3) | 5 (1.1) | 1.15 (.43–3.10) | −15.2 (−210.4–57.3) | 1.00 | 1.61 (.50–5.18) | −61.0 (−418.0–50.2) | .43 |
| HPV45 | 3 (0.2) | 1 (0.1) | 2 (0.4) | 0.17 (.02–1.86) | 83.1 (−86.4–98.5) | .16 | 0.14 (.01–1.95) | 86.5 (−95.0–99.1) | .14 |
| HPV51 | 21 (1.2) | 15 (1.1) | 6 (1.3) | 0.85 (.33–2.17) | 15.3 (−117.0–66.9) | .62 | 0.64 (.22–1.85) | 36.3 (−85.0–78.0) | .41 |
| HPV52 | 50 (2.8) | 33 (2.4) | 17 (3.7) | 0.66 (.37–1.17) | 34.2 (−16.9–63.0) | .14 | 0.52 (.26–1.01) | 48.3 (−1.0–73.6) | .05 |
| HPV56 | 43 (2.4) | 33 (2.4) | 10 (2.2) | 1.12 (.56–2.25) | −11.8 (−125.0–44.5) | 1.00 | 1.51 (.66–3.46) | −51.0 (−246.0–34.5) | .34 |
| HPV58 | 36 (2.0) | 27 (2.0) | 9 (2.0) | 1.02 (.48–2.15) | −1.6 (−114.5–51.8) | 1.00 | 0.73 (.32–1.70) | 26.8 (−70.0–68.5) | .47 |
| HPV59 | 24 (1.3) | 20 (1.5) | 4 (0.9) | 1.69 (.58–4.93) | −69.4 (−392.9–41.8) | .48 | 1.52 (.47–4.98) | −52.0 (−398.0–53.4) | .49 |
| HPV68 | 15 (0.8) | 12 (0.9) | 3 (0.7) | 1.36 (.38–4.78) | −35.5 (−378.0–61.6) | 1.00 | 1.60 (.38–6.80) | −60.0 (−580.0–62.1) | .52 |
Abbreviations: aOR, adjusted odds ratio; aVE, adjusted VE; CI, confidence interval; PR, prevalence ratio.
aDefined as HPV16/18/31/33/35/39/45/51/52/56/58/59/68 (detected by the HCII assay).
bBy the Fisher exact test.
cData are adjusted for fiscal year of birth.
d P <.05.